Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TR 987

Drug Profile

TR 987

Alternative Names: Glucoprime; GLYC-101; MG-3601; TR987

Latest Information Update: 12 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycotex; Novogen
  • Developer Glycotex; SerenaGroup; TR Therapeutics
  • Class Anti-inflammatories; Glucans
  • Mechanism of Action Dectin 1 stimulants; Macrophage stimulants; Toll-like receptor 2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Varicose ulcer; Wounds

Most Recent Events

  • 01 Jan 2017 Cosmetic Laser Dermatology completes a phase II trial for Wounds (In volunteers) in USA (NCT02681224)
  • 01 Sep 2015 Cosmetic Laser Dermatology initiates a phase IIb trial for Wounds (In volunteers) in USA (Topical) (NCT02681224)
  • 11 Aug 2015 No recent reports on development identified - Phase-II for Varicose ulcer in Australia (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top